Merck: FDA to Review Gefapixant for Refractory, Unexplained Chronic Cough

 Merck & Co. on Monday said the U.S. Food and Drug Administration accepted for review its new-drug application for gefapixant for the treatment of refractory chronic cough or unexplained chronic cough in adults.

The Kenilworth, N.J., drugmaker said the FDA set a target action date of Dec. 21 for the review, adding that the agency plans to discuss the application at an advisory committee meeting, which has yet to be scheduled.

Merck said there are currently no approved therapies for the treatment of refractory or unexplained chronic cough.

https://www.marketscreener.com/quote/stock/MERCK-CO-INC-13611/news/Merck-nbsp-FDA-to-Review-Gefapixant-for-Refractory-Unexplained-Chronic-Cough-32571023/